Please assess the completion status of the following clinical trial:

Trial Title: Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and Metformin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Molecular diagnosis of DMD~* Patients 7 - 10 years of age at time of screening~* Ambulant~Exclusion Criteria:~* Previous (3 months or less) or concomitant participation in another therapeutic trial~* Use of L-arginine, L-citrulline or metformin within the last 3 months~* Known individual hypersensitivity to L-citrulline or metformin~* Other chronic disease or clinical relevant limitation of renal, liver, heart function according to discretion of the investigator

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- L-arginine and metformin (Type: EXPERIMENTAL): 7.5 g L-arginine p.o. and 500 mg metformin p.o. per day (3x 2.5 g, respectively 3x 250 mg) for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).